Arana A, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. Authors reply. N Engl J Med. 2010 Nov 4;363(19):1873-4.
Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med. 2010 Aug 6;363(6):542-51.
Arana A, Wentworth CE, Rivero E, Plana E, Conde E. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCIs). Poster presented at the 26th International Conference on Pharmacoepidemiology; August 2010. Brighton, England. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug; 19(S1):S12.
Arana A, Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico MT, Vanhaverbeke N, Wentworth CE, Brosa M, Arellano FM. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation. Drug Saf. 2010 Jun;33(6):489-501.
Huang H, Huang Z, Coulomb S, Lafuma A, Arana A. A drug utilization study of posaconazole in French hospitals. Presented at the 26th International Conference on Pharmacoepidemiology; 2010.
Arana A, Wentworth CE, Arellano FM. Validity of the codes of suicidality in the THIN database. Drug Saf. 2010;19(12):1316-7.
Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010;163(5):1036-43.
Arana A, Arellano F, Wentworth CE, Price J. An algorithm for the diagnosis of suicide in the THIN database. Presented at the 26th International Conference on Pharmacoepidemiology; 2010.
Arellano FM, Arana A, Wentworth CE. Potent topical steroids are the treatment for cutaneous T-cell lymphoma. Allergy. 2010;126(2):414-5.
Conde E, Wentworth CE, Rivero E, Arana A. Lymphoma case ascertainment in the US PharMetrics database. Presented at the 26th International Conference on Pharmacoepidemiology; 2010.
Laudati JT, Jo EJ, Ahmed S, Arana A. Drug utilization physician survey of Intron A® in Europe. Presented at the 26th International Conference on Pharmacoepidemiology; 2010.
Arana A, Castellsague J, Trave F, Perez-Gutthann S, Rothman KJ, Arellano FM. Early estimation of excess risk of serious cutaneous reactions for newly marketed drugs. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):165.
Arana A, Broeckmans AW. Validity of epidemiological research conducted following Good Clinical Practice Guidelines. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.
Tuells A, Arana A, Perez-Gutthann S, García-Rodríguez LA. El Proyecto BIFAP. Inv Clin Farm. 2003;0:25-6.
Sánchez Matienzo D, Gimeno V, Castellsague J, Arana A. Safety profile of smell and taste disorders in patients treated with cox-2 specific inhibitors and other selected drugs. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.
Sánchez Matienzo D, Gimeno V, Castellsague J, Arana A. A comparative safety profile of serious skin and hypersensitivity reactions: cOX-s specific inhibitors vs. non-selective NSAIDs and other selected drugs. Presented at the 19th International Conference on Pharmacoepidemiology; 2003. [abstract] Pharmacoepidemiol Drug Saf. 2003; 12(S1):S185.
Sánchez Matienzo D, Gemino V, Castellsague J, Arana A. Safety profile analysis of liver disorders in patients treated with celecoxib and rofecoxib. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.